Somatostatin receptor scintigraphy (SRS) using 111In-octreotide has proven useful in the
preoperative discrimination of expansive central nervous system lesions. Meningiomas …

111ln-octreotide. Planar whole-body images were obtained at 10 min, 1, 4 and 24 hr
postinjection, and SPECT was performed at 4 and 24 hr postinjection. The final diagnosis …

The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in patients
with meningioma proven or suspected on magnetic resonance imaging (MRI). Prior to …

Meningioma is one of a variety of human tumors that exhibit a very high density of
somatostatin receptors and in many cases show a true positive somatostatin receptor …

The somatostatin analogue [111 In-DTPA-d-Phe 1]-octreotide (111 In-octreotide) allows
scintigraphic visualization of somatostatin receptor-expressing tissue. While it is well known …

Revised: 8 July 2015/Accepted: 10 July 2015/Published online: 21 July 2015© Springer-
Verlag Berlin Heidelberg 2015 following rare histologic variants of meningioma were …

Meningiomas are benign brain tumors that are usually to recur. Studies have shown in vitro
and in vivo that meningiomas, regardless of histology and classification, express …

Somatostatin receptors (SSTRs) have been detected in many normal and malignant tissues.
This wide expression has been used for diagnostic, prognostic and therapeutic purposes …

Meningiomas are the most common non-malignant primary intracranial tumors, accounting
for nearly 40% of all primary brain tumors, usually expressing high levels of somatostatin …

Simple Summary Meningioma diagnostics and grading are currently based on subjective
histopathological criteria given by the 2016 World Health Organization (WHO) classification …